Latest liver disease Stories
FDA approves oral therapy as a first-in-class treatment BALTIMORE, March 17, 2015 /PRNewswire-USNewswire/ -- Asklepion Pharmaceuticals, LLC. today announced that the U.S.
TEL AVIV, Israel, March 17, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
MILFORD, Mass., March 12, 2015 /PRNewswire/ -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of hepatitis B and
LONDON, March 9, 2015 /PRNewswire/ -- SummaryGlobalData's clinical trial report, "Non Alcoholic Fatty Liver Disease (NAFLD) Global Clinical Trials Review, H1, 2015" provides
TEL AVIV, Israel, March 2, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
TEL AVIV, Israel, Feb. 25, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
DALLAS, February 1, 2015 /PRNewswire/ -- RnRMarketResearch.com adds Non Alcoholic Fatty Liver Disease (NAFLD) Global Pipeline and Clinical Trials Review, H1, 2015 research
RnRMarketResearch.com adds “Primary Sclerosing Cholangitis – Pipeline Review, H1 2015” to its store.
TEL AVIV, Israel, Jan. 6, 2015 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.
Dignity Sciences today announced positive results with its anti-fibrotic compound DS102 in preclinical studies which assessed its potential effectiveness for the treatment of non-alcoholic steatohepatitis
- The governor of a province or people.